One (colorectal cancer with BRAF V600K mutation by the CLIA, but not Idylla) of four patients with discrepant BRAF V600 mutation status between the CLIA laboratory and Idylla received a MEK inhibitor with disease progression and one patient (melanoma with BRAF V600E mutation by the CLIA, but not Idylla) received a combination of BRAF inhibitor with chemotherapy and responded for 3 months. This evidence concerns the gene MAP2K7 and melanoma.